This outbreak of Ebola disease caused by the Bundibugyo virus (BDBV) once again exposes persistent failures to ensure that accessible medical tools for diseases disproportionately affecting low-and middle-income countries(LMICs)are prioritised, funded, and produced as part of research and development (R&D)processes. This is reflected in the current absence of tested and validated therapeutics and the limited availability of diagnostic tools, the latter gap occurring despite experts clearly having identified the need for broader diagnostics for Ebola disease following the Bundibugyo virus outbreaks of 2007 and 2012.In this context ,rapid initiatives, resources and actions are being mobilised at national, regional and international levels in response to the current Ebola disease outbreak. It’s now critical to not only to respond swiftly but also to apply lessons learned from past epidemics, including COVID-19 and previous Ebola disease outbreaks, and ensure that transparent, accountable and enforceable access arrangements are embedded in R&D from the outset so that priority medical tools reach the most affected communities in a timely and equitable manner. MSF, therefore, urges donor agencies, governments and research institutions to consider the principles highlighted in this video to ensure equitable access to medical tools for BDBV